David Bell , Garrett W. Brown , Wellington A. Oyibo , Samiratou Ouédraogo , Blagovesta Tacheva , Elena Barbaud , Andreas Kalk , Valéry Ridde , Elisabeth Paul
{"title":"COVAX – Time to reconsider the strategy and its target","authors":"David Bell , Garrett W. Brown , Wellington A. Oyibo , Samiratou Ouédraogo , Blagovesta Tacheva , Elena Barbaud , Andreas Kalk , Valéry Ridde , Elisabeth Paul","doi":"10.1016/j.hpopen.2023.100096","DOIUrl":null,"url":null,"abstract":"<div><p>COVAX, the international initiative supporting COVID-19 vaccination campaigns globally, is budgeted to be the costliest public health initiative in low- and middle-income countries, with over 16 billion US dollars already committed. While some claim that the target of vaccinating 70% of people worldwide is justified on equity grounds, we argue that this rationale is wrong for two reasons. First, mass COVID-19 vaccination campaigns do not meet standard public health requirements for clear expected benefit, based on costs, disease burden and intervention effectiveness. Second, it constitutes a diversion of resources from more cost-effective and impactful public health programmes, thus reducing health equity. We conclude that the COVAX initiative warrants urgent review.</p></div>","PeriodicalId":34527,"journal":{"name":"Health Policy Open","volume":"4 ","pages":"Article 100096"},"PeriodicalIF":1.7000,"publicationDate":"2023-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/b1/main.PMC10098302.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Policy Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590229623000084","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 2
Abstract
COVAX, the international initiative supporting COVID-19 vaccination campaigns globally, is budgeted to be the costliest public health initiative in low- and middle-income countries, with over 16 billion US dollars already committed. While some claim that the target of vaccinating 70% of people worldwide is justified on equity grounds, we argue that this rationale is wrong for two reasons. First, mass COVID-19 vaccination campaigns do not meet standard public health requirements for clear expected benefit, based on costs, disease burden and intervention effectiveness. Second, it constitutes a diversion of resources from more cost-effective and impactful public health programmes, thus reducing health equity. We conclude that the COVAX initiative warrants urgent review.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
